title: Partnering for Vaccine Emerging Markets--Berlin, June 10-11, 2013: balancing vaccine quality, capacity, and cost-of-goods in emerging markets.
abstract: Phacilitates 1st Partnering event for Vaccine Emerging Markets brought together approximately 100 attendees from developed and developing world vaccine manufacturers, leading non-profit organizations and industry suppliers. The goal was to discuss the vaccine needs in the developing world and how these needs can be met by leveraging collaboration and partnership models, by improving access to existing, new and next generation vaccines, by using novel technologies to drive competitive advantage and economics of vaccine manufacturing and by investing in localized capacity, including capacity for pandemic vaccines. The present article summarizes insights out of 30 oral contributions on how quality and capacity requirements can be balanced with cost by using novel manufacturing technologies and operating models.
authors: Global Vaccine Market Manager; Pall International; Fribourg, Switzerland.
authors: Annelies
authors: A
authors: Onraedt
mesh_terms: D001604:Berlin; D003906:Developing Countries; D006801:Humans; D055818:Public-Private Sector Partnerships / Q000458:organization & administration*; D013678:Technology, Pharmaceutical / Q000191:economics / Q000379:methods / Q000639:trends; D014611:Vaccination / Q000191:economics / Q000379:methods* / Q000639:trends*; D014612:Vaccines / Q000191:economics / Q000302:isolation & purification* / Q000600:supply & distribution*
chemical_list: D014612:Vaccines
keywords: capacity; economics; emerging markets; flexible manufacturing; quality; single-use; vaccines